Organization & Developments: Kineta

Parents

2024: Kineta stock falls ~25.7% after co cuts workforce by 64%, including CEO
Iinvolves collaborators at the University of Washington, UC Irvine, University of Oregon, and University of Utah.
It’s supposed to work by taking a small amount of money to conduct early-stage clinical trials of a drug, and then generate liquid returns when a bigger drugmaker pays to license the drug for late-stage development.
Kineta has an unusual model in which it hopes to generate relatively fast returns for investors.
Kineta has said its goal is to make that handoff to a bigger company after about three years of development work.
The first part of the contract was designed to set up computational infrastructure for the project
The project is focused on five disease categories, including cardiovascular, neurological, infectious disease, metabolic disorders, and autoimmunity